Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis

Inclusion Criteria:

Written informed consent and legal representative's permission for study participation obtained prior to beginning of participation in the study.
Age ≥6 to <18 years old.
Established diagnosis of active moderate-to-severe plaque psoriasis defined as a PASI score ≥ 10, body surface area (BSA) involvement of ≥10% and PGA score ≥ 3 only or with concomitant psoriatic arthritis.
Failure or intolerance of prior psoriasis treatment.
Patient was prescribed with secukinumab within 4-16 weeks before inclusion.
Decision for secukinumab prescription was made by the attending physician according to the approved national label during routine clinical practice, regardless of this non-interventional study conduct.

Exclusion Criteria:

Known or suspected severe hypersensitivity for secukinumab, formulation excipients, or injection device components (i.e., latex).
History of chronic recurrent infection.
Clinically significant infection exacerbation, including active tuberculosis.
Age <6 years or ≥18 years.
Pregnancy and breastfeeding.
Patients participating in parallel in an interventional clinical trial.
Patients participating in parallel in other Novartis-sponsored non-interventional study generating primary data for secukinumab.
Patients within the safety follow-up phase of interventional study.
Active inflammatory bowel disease at inclusion.
Patients who received any vaccine within 4 weeks prior to secukinumab initiation.
Any medical or psychological condition in the investigator's opinion which may prevent the study participation.